Advertisement

Topics

[Comment] New-generation JAK inhibitors: how selective can they be?

11:53 EDT 13 Jun 2018 | The Lancet

Almost 20 years into the biologics era, an unmet need exists for treating patients with rheumatoid arthritis and other inflammatory diseases who either do not tolerate, do not respond to, or cannot afford effective but costly biologic medicines. Also 20 years ago, the small family of Janus kinases (or tyrosine-protein kinase JAK; JAKs) were discovered, and have since been harnessed for treating and understanding both malignancies and inflammatory diseases.

Original Article: [Comment] New-generation JAK inhibitors: how selective can they be?

NEXT ARTICLE

More From BioPortfolio on "[Comment] New-generation JAK inhibitors: how selective can they be?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...